Pre-made Narsoplimab benchmark antibody ( Whole mAb, anti-MASP2 therapeutic antibody, Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-366
Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Narsoplimab is the company's lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis|
|Conditions Discontinued||Stroke;Wet age-related macular degeneration|